vuk8691/iStock via Getty Images Investment Overview I last covered Biogen (NASDAQ:BIIB), the Cambridge, Massachusetts based pharmaceutical company, focused primarily on central nervous system diseases, for Seeking Alpha in April this year, shortly after the company announced its Q1 2024 earnings - revenues of $1.71bn, down 3% year-on-year, and non-GAAP earnings per share ("EPS") of $3.7, up 8% year-on-year - giving the stock a "Buy" Recommendation. Nearly four months on, and with Q2 earnings having been ...